Immunic to Participate in Investor and Scientific Conferences in May
-
May 12-14 and 21-22: Bio€quityEurope 2024.Jessica Breu , Vice President Investor Relations and Communications atImmunic , will attend and host one-on-one investor meetings at this conference taking place in San Sebastián,Spain and virtually. To schedule a meeting, please use the Bio€quity conference portal or contactJessica Breu at: jessica.breu@imux.com. -
May 18-21 : Digestive Disease Week (DDW) 2024. Franziska Buriánek, M.D., Senior Medical Director atImmunic , will present data fromImmunic's phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, in an oral presentation at this conference inWashington, DC . The presentation will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.- Presentation Title: First In Human Trial Of IMU-856, An Orally Available Epigenetic Modulator Of Barrier Regeneration For The Treatment Of Celiac Disease
- Abstract ID: 4025905
- Session Title: Since Sliced Bread: Best in Celiac 2024
- Session Type:
Research Forum - Session Date:
Monday, May 20, 2024 - Session Time:
2:00 - 3:30 pm EDT
-
May 29 - June 1 : TheConsortium of Multiple Sclerosis Centers (CMSC) 38th Annual Meeting.Robert J. Fox , M.D., Staff Neurologist,Mellen Center for Multiple Sclerosis , Vice-Chair for Research,Neurological Institute ,Cleveland Clinic ,Cleveland, Ohio will present interim data fromImmunic's phase 2 CALLIPER trial of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) at this meeting inNashville, TN. The poster presentation will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.- Poster Title: Impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS: Assessment from the CALLIPER Interim Analysis
- Abstract ID: 9651
- Poster Session Date:
Thursday, May 30, 2024 - Poster Session Time:
5:15 - 7:15 pm CDT (6:15 - 8:15 pm EDT )
-
May 30 - June 2 :XXIII National Congress of Neurology . Sonya Ivanova Hristova-Chakmakova, M.D., Assistant Professor,Multiprofile Hospital for Active Treatment in Neurology and Psychiatry «St. Naum»,Sofia, Bulgaria , will present data fromImmunic's phase 2 CALLIPER trial in an oral presentation at this conference inGolden Sands ,Bulgaria . The presentation will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.- Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial
- Poster ID: 201
- Poster Session: 2
- Date:
Thursday, May 30, 2024 - Time:
2:00pm EEST (7:00am EDT )
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.
Contact Information
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-may-302135622.html
SOURCE